Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy

Cancer Science

Volumn 106, Issue 9, 2015, Pages 1111-1117

  Kawano, Kouichiro ^a   Tsuda, Naotake ^a   Waki, Kayoko ^b   Matsueda, Satoko ^b   Hata, Yoshiro ^b   Ushijima, Kimio ^a   Itoh, Kyogo ^b   Yamada, Akira ^b   Kamura, Toshiharu ^a,c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c Yanagawa Hospital   (Japan)

Author keywords

Cervical cancer; Cytotoxic T lymphocytes; Epitopes; Peptide vaccine; Personalized medicine

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CANCER VACCINE; CD4 ANTIGEN; CREATININE; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A3 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; PEPTIDE VACCINE; PERSONALIZED PEPTIDE VACCINE; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PLATINUM COMPLEX; SUBUNIT VACCINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTOVAGINAL FISTULA; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HLA SYSTEM; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; LEUKOPENIA; LUNG HEMORRHAGE; LYMPHOCYTOPENIA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; SIDE EFFECT; UPPER RESPIRATORY TRACT BLEEDING; UTERINE CERVIX CANCER; VACCINATION REACTION; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

ADULT; AGED; CANCER VACCINES; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PRECISION MEDICINE; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, SUBUNIT;

EID: 84942193410     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12729     Document Type: Article

References (24)

1. International Agency for Research on Cancer. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Cited 22 January 2015.] Available from URL: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Leath CA III, Straughn JM Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooporative group trials. Gynecol Oncol 2013; 129: 251-7.
3. Tewari KS, Sill MW, Long HJ III et al. Improved survival with Bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734-43.
4. Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 970-6.
5. Sasada T, Yamada A, Noguchi M, Itoh K. Personalized Peptide vaccine for treatment of advanced cancer. Curr Med Chem 2014; 21: 2332-45.
6. Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009; 58: 1843-52.
7. Yanagimoto H, Shiomi H, Satoi S et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795-801.
8. Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 337-44.
9. Kawano K, Tsuda N, Matsueda S et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacol Immunotoxicol 2014; 36: 224-36.
10. Noguchi M, Kakuma T, Uemura H et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 1001-9.
11. Komatsu N, Shichijo S, Maeda Y et al. Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system. J Immunol Methods 2002; 263: 169-76.
12. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013; 62: 919-29.
13. Rose PG, Blessing JA, Arseneau J. Phase II evaluation of altertamine for advanced and recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 100-2.
14. Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77: 446-9.
15. Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 89: 267-70.
16. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2005; 96: 103-7.
17. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 1069-74.
18. Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10: 929-37.
19. Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10: 1266-79.
20. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60: 433-42.
21. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388-97.
22. Waki K, Yamada T, Yoshiyama K et al. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci 2014; 105: 1229-35.
23. Yutani S, Komatsu N, Matsueda S et al. Juzentaihoto failed to augment antigen-specific immunity but prevented deterioration of patients' conditions in advanced pancreatic cancer under personalized peptide vaccine. Evid Based Complement Alternat Med 2013; 2013: 981717.
24. Kibe S, Yutani S, Motoyama S et al. Phase II Study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res 2014; 2: 1154-62.